Cantor Fitzgerald Pacific Biosciences Prices $86.9M Public Stock Offering The sequencing firm is offering 19.4 million shares of common stock at $4.47 per share and plans to use the proceeds for product launches, among other uses. HTG Molecular Diagnostics Files for $20M Stock Offering The Tucson, Arizona-based company previously raised $20 million through a public offering of its shares and a purchase deal with certain investors. Cantor Fitzgerald Downgrades PerkinElmer to Neutral The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration. Cantor Fitzgerald Initiates Coverage on Rosetta Genomics, Veracyte The investment bank initiated coverage on Rosetta Genomics and Veracyte, rating the molecular diagnostic firms' shares speculative buy and buy, respectively. Cancer Genetics, Cantor Fitzgerald Reach $20M Stock Sales Agreement The company also said that its cash burn rate for Q2 is estimated to be about $4.8 million, or $1.3 million more than its average cash burn. Feb 4, 2015 PacBio, Cantor Fitzgerald Amend Deal to Offer up to $30M in Stock Breaking News GenomeWeb Index Falls 6 Percent in November as Emergence of Omicron Spooks Markets Sequencing-Based MRD Detection in Bone Marrow May Predict ALL Relapse After CAR T-Cell Therapy Metabolomic Study Links 13 Metabolites to Coronary Heart Disease Risk Among African Americans Illumina Wins $8M Jury Verdict in BGI Patent Infringement Suit, Loses Patent Caris Life Sciences Facing FTC Lawsuit After Resisting Subpoena in Illumina, Grail Antitrust Case Biodesix, Spesana Partner to Improve Workflows for Lung Cancer Molecular Diagnostic Tests The Scan Panel Votes for COVID-19 Pill A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says. But Not Harm New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare. Effectiveness Drop Anticipated Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports. Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.